Metadata Search Funding Data Link References Status API Help
Facet browsing currently unavailable
Page 2 of 57328 results
Sort by: relevance publication year
Showing results for ISSN matching 0923-7534

971P Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Authors: Z. Fan | T. Yang | L-H. Gu | W. Qiu | Y-J. Liang | X-M. Wang | F. Shen | C. Li | M. Wang

https://doi.org/10.1016/j.annonc.2023.09.2116 Actions

1923P Combined analysis of phase III ANNOUNCE study and phase II study exploring olaratumab in advanced soft tissue sarcoma

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Authors: Y. Naito | K. Sakamaki | S. Morita | T. Mukohara | T. Akimoto

https://doi.org/10.1016/j.annonc.2023.09.1152 Actions

2115P Pre-cachexia incidence in patients with solid cancer: A cross-sectional study

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Authors: L. Gottmann | L. Berchtold | M. Mair | A.M. Starzer | J.H. Fürst | J.M. Berger | C. Englisch | M. Kleinberger | M. Korpan | E. Hütterer | E.S. Bergen | M. Preusser | A.S. Berghoff

https://doi.org/10.1016/j.annonc.2023.09.897 Actions

1903P Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Authors: V. Gruenwald | R.R. McKay | T. Buchler | M. Eto | S.H. Park | T. Takagi | S. Zanetta | D. Keizman | C. Suarez Rodriguez | S. Negrier | J-L. Lee | D. Santini | J. Bedke | M. Staehler | C.K. Kollmannsberger | T.K. Choueiri | R.J. Motzer | J. Burgents | C.E. Okpara | T.B. Powles

https://doi.org/10.1016/j.annonc.2023.09.1133 Actions

517P Differentiating IDH-wildtype and IDH-mutant high grade gliomas with deep learning

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Authors: K.J. Hewitt | C.M.L. Loeffler | M. van Treeck | H. Muti | G. Veldhuizen | O. Saldanha | L. Bejan | T. Millner | S. Brandner | J.N. Kather

https://doi.org/10.1016/j.annonc.2023.09.1711 Actions

287P Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Authors: J. Staaf | S. Veerla | L. Hohmann | D.F. Nacer | J. Vallon-Christersson

https://doi.org/10.1016/j.annonc.2023.09.484 Actions

15P CBL E3 ubiquitin ligases are key inhibitory regulators in PD-1/LAG-3 co-signaling in human cancers, targeted through bispecific co-blockade

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Authors: L. Chocarro | L. Fernández-Rubio | M.J. Garcia Granda | E. Blanco Palmeiro | A.I. Bocanegra Gondan | M. Echaide | M. Garnica | M. Zuazo | C. Johnston | C.J. Edwards | J. Leggs | A. Pierce | H. Arasanz | R. Vera | K. Ausin | E. Santamaría | J. Fernández-Irigoyen | G. Kochan | D. Escors

https://doi.org/10.1016/j.annonc.2023.09.1518 Actions

2034MO EAGER: A randomized, controlled, multicenter trial of electro-acupuncture in gastric cancer patients undergoing adjuvant chemotherapy

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Research funded by National Key Research and Development Program of China (2017YFC1700603)

Authors: H-B. Zhang | Y. Zhu | J.J. Mao | X-S. Chang | J-J. Peng | X-Y. Wu | W. Wang | D-C. Diao | Y. Li | H-Y. Zhang | X-H. Zhai | J-L. Yu | W. Wang | J-X. Zhou | Z-L. Huang | T. Zhang | Y-H. Liu | R. Zhou | H-C. Ma | Y-D. Chen

https://doi.org/10.1016/j.annonc.2023.09.817 Actions

1173P NRAS mutation as an independent prognostic factor for resectable Chinese acral melanoma

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Research funded by Shanghai Science and Technology Development Foundation (9411951700,LG-QS-202205-11) | National Natural Science Foundation of China (81802636)

Authors: Y. Xu | X. Lin | X. Liu | W. Sun | T. Hu | W. Yan | C. Wang | X. Zhang | Z. Luo | Y. Chen

https://doi.org/10.1016/j.annonc.2023.09.2989 Actions

985P Characteristics and outcomes in patients (pts) with unresectable hepatocellular carcinoma (uHCC) who initiated second-line (2L) therapy after receiving first-line (1L) atezolizumab plus bevacizumab (atezo+bev) and in those who did not

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Authors: A. Singal | K. Ozgurdal | Z. Vassilev | F. Pisa | W. John | P. Pathak | S. Gordon | X. Pan

https://doi.org/10.1016/j.annonc.2023.09.2130 Actions

P-304 CDH1 and CTNNA1 negative hereditary diffuse gastric carcinoma cases: Genetic susceptibility variants and their potential impacts

JOURNAL ARTICLE published June 2023 in Annals of Oncology

Research funded by Ministère de l’Enseignement Supérieur et de la Recherche Scientifique (LR16IPT05)

Authors: J. Ben Aissa-Haj | M. Kabbage | H. Guettiti Tounsi-Kettiti | S. Abdelhak | S. Boubaker | E. Rouleau

https://doi.org/10.1016/j.annonc.2023.04.360 Actions

P-102 Unmet needs of patients during colorectal cancer care and treatment – a qualitative study through an online patient community

JOURNAL ARTICLE published June 2023 in Annals of Oncology

Authors: E. Samalin | L. Lorenzon | C. Sarrauste de Menthière | L. Guéroult-Accolas | R. Paixão | C. Chaves Almagro | E. Pain | E. Martinelli

https://doi.org/10.1016/j.annonc.2023.04.158 Actions

196P Serum metabolomics to determine survival of immunotherapy for advanced non-small cell lung cancer: Metabolomic analysis based on two cohorts

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Authors: Y. Xu | K. Ding | Z. Peng | Y. Fan

https://doi.org/10.1016/j.annonc.2023.09.2919 Actions

1317MO Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC)

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Authors: Y. Ma | H. Zhao | Y. Zhao | Y. Cheng | J. Cui | G. Liu | D. Xiong | J. Zhang | L. Xu | J. Yu | L. Men | E. Liang | D. Yang | L. Zhang | Y. Zhai

https://doi.org/10.1016/j.annonc.2023.09.2351 Actions

375TiP A phase I, 2-part, multicenter, first-in-human dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Authors: L. Cavalcante | L.L. Siu | J. Toso | D. Mires | R. Shiga | J. Maruca | G. Ayele | P. Kumar Vuppala | Y. Cheng | L. Huang | J.E. Connolly | Y. Ishimoto | M. Sue | P.L. Bedard

https://doi.org/10.1016/j.annonc.2023.09.2830 Actions

56P SLC34A2-ROS1 L2026M+G2032R confers resistance to ROS1 tyrosine kinase inhibitors in Ba/F3 cells through a reduced ATP binding pocket volume

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Authors: C. Dijkhuizen | P. Korthuis | J. Vilacha | M. Smelt | A.J. Van Der Wekken | A. van den Berg | L. Drayer

https://doi.org/10.1016/j.annonc.2023.09.1557 Actions

1701P Cancer premium: Explaining differences in prices for cancer vs non-cancer drugs with efficacy and epidemiological endpoints in the US, Germany, and Switzerland

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Authors: M. Serra-Burriel | G. Perényi | Y. Laube | A. Mitchell | K.N. Vokinger

https://doi.org/10.1016/j.annonc.2023.09.2655 Actions

1828P ARX517: A next generation anti-PSMA antibody drug conjugate (ADC) demonstrates notable stability and pharmacokinetic (PK) profile in the ARX517 phase I clinical trial (APEX-01)

JOURNAL ARTICLE published October 2023 in Annals of Oncology

Authors: S.T. Tagawa | J. Shen | L. Skidmore | J. Nelson | R. Pachynski | S. Zhang

https://doi.org/10.1016/j.annonc.2023.09.2776 Actions

P-255 MiR-373-3p inhibits proliferation, invasion and stemness of gastric cancer by targeting CD44

JOURNAL ARTICLE published June 2023 in Annals of Oncology

Research funded by National Natural Science Foundation of China (81972790,82103593)

Authors: B. Zhang | K. Zhang | L. Chen

https://doi.org/10.1016/j.annonc.2023.04.311 Actions

1753P Cost-effectiveness (CE) of nivolumab (NIVO) as adjuvant treatment of muscle invasive urothelial carcinoma at high risk of recurrence (MIUC-HR) in France

JOURNAL ARTICLE published September 2022 in Annals of Oncology

Authors: M.S. Negrier | F.P. Colrat | J. Bonastre | C. Chamielec | S. Teitsson | C. Knight | L. Ni | J. Chevalier | A-F. Gaudin | M. Roupret | S. Branchoux

https://doi.org/10.1016/j.annonc.2022.07.1831 Actions
Feedback: support@crossref.org